



Angiogenesis

Guest Editors:

Dr. Angela Orecchia

Laboratory of Molecular and Cell
Biology, IDI-IRCCS, Rome, Italy

Dr. Cristina M. Failla

Experimental Immunology
Laboratory, IDI-IRCCS, Rome,
Italy

Deadline for manuscript
submissions:
closed (31 October 2024)

Message from the Guest Editors

Angiogenesis is the growth of blood vessels from the existing vasculature: metabolically active tissue is no more than a few hundred micrometers from a blood capillary, which is formed through the process of angiogenesis.

Angiogenesis occurs throughout life in both healthy subjects and subjects suffering from a disease; therefore, the control of angiogenesis has a therapeutic value and has been a field of significant interest during the past 40 years research.

One group of essential growth factor receptors in angiogenesis are vascular endothelial growth factor receptors (VEGFRs), a subfamily of receptor tyrosine kinases (RTKs). Multiple VEGF ligands with different preference and capability bind to VEGFRs and activate them in homo- and heterodimeric manners, representing a challenge for the study of their selective biochemical and cellular signaling in endothelial cell backgrounds and the role in leading angiogenesis processes.

This Special Issue welcomes original articles and reviews focused on the novelties in the angiogenesis field both in human health and disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)